Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCI-196 (Colestilan) in dialysis patients with hyperphosphatemia
NCT00542815Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma
- Start
- Nov 2007
- Primary completion
- Aug 2010
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 3, open-label trial of colestilan in hyperphosphatemia (2 arms), sponsored by Mitsubishi Tanabe Pharma. Primary endpoint: Change in Serum Phosphorus at 52 weeks. Started Nov 2007; status: completed.
02
Drugs
colestilan
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT00542815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00542815.